日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study

Simlukafusp alfa (FAP-IL2v) 联合阿特珠单抗,加或不加贝伐珠单抗,用于治疗不可切除的转移性肾细胞癌:一项随机、开放标签的 Ib 期研究

Perez-Gracia, Jose Luis; Mellado, Begoña; Hansen, Aaron Richard; Alonso-Gordoa, Teresa; Gomez-Roca, Carlos; Løvendahl Eefsen, Rikke; Negrier, Sylvie; Suárez, Cristina; Lee, Jae-Lyun; Hussain, Arif; Pedrazzoli, Paolo; Moreno, Victor; Rodriguez-Vida, Alejo; Sosman, Jeffrey Alan; Waddell, Tom; Bedke, Jens; Park, Se Hoon; Sznol, Mario; Spychaj, Lukasz; Andersson, Emilia; Julien-Laferriere, Alice; Cheng, Wei-Yi; Watson, Carl; Silva, Ana Patricia; Heichinger, Christian; Staedler, Nicolas; Sleiman, Nassim; Dejardin, David; Boetsch, Christophe; Evers, Stefan; Vardar, Taner; Ardeshir-Tandon, Caroline; Dorado Pérez, Jorge; Charo, Jehad; Keshelava, Nino; Kraxner, Anton; Teichgräber, Volker; Powles, Thomas

Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study

KEYNOTE-564 III期研究东亚亚组中肾细胞癌辅助治疗帕博利珠单抗与安慰剂的比较

Park, Se Hoon; Chang, Yen-Hwa; Lee, Jae Lyun; Choueiri, Toni K; Kimura, Go; Chung, Jinsoo; Masumori, Naoya; Nishimura, Kazuo; Kato, Minoru; Kato, Haruaki; Numakura, Kazuyuki; Chang, Chao-Hsiang; Anai, Satoshi; Tsunemori, Hiroyuki; Chen, Chung-Hsin; Lin, Jianxin; Elfiky, Aymen; Burgents, Joseph E; Kitamura, Hiroshi

A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTIMA; KCSG GU20-03)

一项多中心 II 期研究,评估改良 FOLFIRINOX 方案一线治疗晚期脐尿管癌的疗效(ULTIMA;KCSG GU20-03)

Park, Inkeun; Lee, Jae Lyun; Yoon, Shinkyo; Shin, Sang Joon; Shin, Seong-Hoon; Kim, Jung Hoon; Park, Kwonoh; Lee, Hyo Jin

How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study

与铂类化疗相比,恩福妥单抗联合帕博利珠单抗治疗对晚期尿路上皮癌患者生活质量的影响:EV-302 研究患者报告结局的简明语言总结

Gupta, Shilpa; Loriot, Yohann; Van der Heijden, Michiel S; Bedke, Jens; Valderrama, Begoña P; Kikuchi, Eiji; Fléchon, Aude; Petrylak, Daniel; De Santis, Maria; Galsky, Matthew D; Lee, Jae Lyun; Swami, Umang; Sridhar, Srikala S; De Giorgi, Ugo; Wright, Phoebe; Shih, Vanessa; Lu, Yi-Tsung; Guan, Xuesong; Dillon, Ryan; Shetty, Aditya; Homet Moreno, Blanca; Beaumont, Jennifer L; Purnajo, Intan; McManus, Shauna; Powles, Thomas

The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group

韩国癌症研究组开展的研究者发起试验的生存率和经济效益

Kim, Bum Jun; Maeng, Chi Hoon; Keam, Bhumsuk; Im, Young-Hyuck; Ro, Jungsil; Jung, Kyung Hae; Im, Seock-Ah; Kim, Tae Won; Lee, Jae Lyun; Heo, Dae Seog; Kim, Sang-We; Park, Keunchil; Ahn, Myung-Ju; Cho, Byoung Chul; Kim, Hoon-Kyo; Kang, Yoon-Koo; Cho, Jae Yong; Yun, Hwan Jung; Nam, Byung-Ho; Zang, Dae Young

Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05)

培美曲塞维持治疗与观察治疗在完成一线铂类化疗且未出现疾病进展的晚期尿路上皮癌患者中的疗效比较(PREMIER,KCSG GU16-05)

Park, Inkeun; Yoon, Shinkyo; Kim, Ilhwan; Park, Kwonoh; Lee, Suee; Keam, Bhumsuk; Park, Joo-Hwan; Kim, Jin Young; Choi, Yoon Ji; Sohn, Byeong Seok; Lee, Jae Lyun

Significant Dissatisfaction with an Outdated System: A Survey on the Experience of Application for Off-Label Use of Anti-cancer Drugs by the Korean Society of Medical Oncology

对过时制度的强烈不满:韩国肿瘤内科学会抗癌药物超适应症用药申请经验调查

Lee, Jae Lyun; Koo, Dong-Hoe; Won, Young-Woong; Kim, Young Saing; Ahn, Hee Kyung; Lim, Seungtaek

Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma

晚期尿路上皮癌患者的身体成分和免疫治疗结果

Kim, Sojin; Yoon, Shinkyo; Park, Inkeun; Lee, Jae Lyun; Jeong, Hyehyun; Ko, Yousun; Kim, Kyung Won; Kim, Sun Young

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Xaluritamig,一种针对转移性去势抵抗性前列腺癌的STEAP1 × CD3 XmAb 2+1免疫疗法:首次人体试验剂量探索结果

Kelly, William K; Danila, Daniel C; Lin, Chia-Chi; Lee, Jae-Lyun; Matsubara, Nobuaki; Ward, Patrick J; Armstrong, Andrew J; Pook, David; Kim, Miso; Dorff, Tanya B; Fischer, Stefanie; Lin, Yung-Chang; Horvath, Lisa G; Sumey, Christopher; Yang, Zhao; Jurida, Gabor; Smith, Kristen M; Connarn, Jamie N; Penny, Hweixian L; Stieglmaier, Julia; Appleman, Leonard J

Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial

罗加替尼联合阿特珠单抗治疗不适合顺铂治疗的FGFR RNA过表达尿路上皮癌患者:FORT-2 1b期非随机临床试验

Sweis, Randy F; Gajate, Pablo; Morales-Barrera, Rafael; Lee, Jae-Lyun; Necchi, Andrea; de Braud, Filippo; Penel, Nicolas; Grünwald, Viktor; Maruzzo, Marco; Meran, Johannes; Ishida, Tatiane Cristine; Bao, Weichao; Zhou, Yinghui; Ellinghaus, Peter; Rosenberg, Jonathan E